PropertyValue
?:abstract
  • Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
?:creator
?:doi
?:doi
  • 10.2169/internalmedicine.5244-20
?:journal
  • Intern_Med
?:license
  • cc-by-nc-nd
?:pdf_json_files
  • document_parses/pdf_json/06a8f9e450ad9781a8c8311a2e27303a1a6848d4.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7725631.xml.json
?:pmcid
?:pmid
?:pmid
  • 32963155.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19
?:type
?:year
  • 2020-09-19

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/eyfu2uwk>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/eyfu2uwk>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all